US-based Nektar Therapeutics has signed a definitive agreement to divest its Huntsville, Alabama manufacturing facility and ...

On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Fintel reports that on November 4, 2024, Piper Sandler initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a ...

Piper Sandler has initiated coverage on Nektar Therapeutics Inc (NASDAQ:NKTR), citing the company’s lead asset ...

Therapeutics announced that it has entered into a definitive agreement to sell its Huntsville, Alabama manufacturing facility and ...

Nektar Therapeutics (Nasdaq: NKTR), a global biotechnology company focused on the discovery and development of novel therapies to treat autoimmune disorders, today announced that it has entered into a ...

Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same quarter in the prior year, the firm earned ($0.27) earnings per share.

Nektar Therapeutics (Nasdaq: NKTR), today announced the publication of peer-reviewed data from two Phase 1b studies in Nature Communications highlighting the efficacy, safety, and tolerability of ...

Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a ...

After Close of U.S.-Based Financial Markets Nektar Therapeutics will announce its financial results for the third quarter 2024 on Thursday, November 7, 2024, after the close of U.S.-based financial ...

It is wholly-owned by Nektar Therapeutics. This press release contains forward-looking statements which can be identified by words such as: "will," "can," "expect," "develop," "potential," "advance," ...